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ABSTRACT Hepatitis C virus (HCV) infection has been shown to regulate microRNA
130a (miR-130a) in patient biopsy specimens and in cultured cells. We sought to
identify miR-130a target genes and to explore the mechanisms by which miR-130a
regulates HCV and hepatitis B virus (HBV) replication. We used bioinformatics soft-
ware, including miRanda, TargetScan, PITA, and RNAhybrid, to predict potential miR-
130a target genes. miR-130a and its target genes were overexpressed or were
knocked down by use of small interfering RNA (siRNA) or clustered regularly inter-
spaced short palindromic repeat (CRISPR)/Cas9 guide RNA (gRNA). Selected gene
mRNAs and their proteins, together with HCV replication in OR6 cells, HCV JFH1-
infected Huh7.5.1 cells, and HCV JFH1-infected primary human hepatocytes (PHHs)
and HBV replication in HepAD38 cells, HBV-infected NTCP-Huh7.5.1 cells, and HBV-
infected PHHs, were measured by quantitative reverse transcription-PCR (qRT-PCR)
and Western blotting, respectively. We selected 116 predicted target genes whose
expression was related to viral pathogenesis or immunity for qPCR validation. Of
these, the gene encoding pyruvate kinase in liver and red blood cell (PKLR) was con-
ﬁrmed to be regulated by miR-130a overexpression. miR-130a overexpression (via a
mimic) knocked down PKLR mRNA and protein levels. A miR-130a inhibitor and
gRNA increased PKLR expression, HCV replication, and HBV replication, while miR-
130a gRNA and PKLR overexpression increased HCV and HBV replication. Supple-
mental pyruvate increased HCV and HBV replication and rescued the inhibition of
HCV and HBV replication by the miR-130a mimic and PKLR knockdown. We con-
cluded that miR-130a regulates HCV and HBV replication through its targeting of
PKLR and subsequent pyruvate production. Our data provide novel insights into key
metabolic enzymatic pathway steps regulated by miR-130a, including the steps in-
volving PKLR and pyruvate, which are subverted by HCV and HBV replication.
IMPORTANCE We identiﬁed that miR-130a regulates the target gene PKLR and its
subsequent effect on pyruvate production. Pyruvate is a key intermediate in several
metabolic pathways, and we identiﬁed that pyruvate plays a key role in regulation
of HCV and HBV replication. This previously unrecognized, miRNA-regulated antiviral
mechanism has implications for the development of host-directed strategies to inter-
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rupt the viral life cycle and prevent establishment of persistent infection for HCV,
HBV, and potentially other viral infections.
KEYWORDS PKLR, hepatitis B virus, hepatitis C virus, microRNA, pyruvate
MicroRNAs (miRNAs) are a class of noncoding small RNA molecules (about 22nucleotides) which regulate gene expression through RNA silencing and post-
transcriptional regulation (1). Growing evidence demonstrates that miRNAs play an
important role in the regulation of metabolism, viral infection, and host immunity
(2–12). miRNAs have been reported as a new class of regulators of metabolism as well
as viral infection (4, 8–10, 12–14).
Immunity and metabolism play pivotal roles in maintaining human homeostasis and
host defenses, especially in response to external stimuli, such as viral infection (15–19).
The energy metabolism of host cells is important for both host and virus, as viruses
strictly depend on the host’s energy and biosynthetic pathways for their replication and
morphogenesis. Pyruvate (also known as pyruvic acid) is a key intermediate in several
metabolic pathways. It is generated from glucose through glycolysis, where the phos-
phoenolpyruvate (PEP) step is catalyzed by pyruvate kinase (PK) (20). There are four
tissue-speciﬁc isozymes of PK in vertebrates. The L (liver) and R (erythrocytes) isozymes
are encoded by the same gene (PKLR). Pyruvate kinase isoenzyme L (PKL) is expressed
primarily in hepatocytes.
Hepatitis C virus (HCV) chronically infects over 71 million people and hepatitis B
virus (HBV) infects over 240 million people worldwide, and these viruses are the leading
causes of chronic viral liver disease (21–24). HCV and HBV share many common
characteristics despite their distinctly different genome structures. Both HBV and HCV
infections induce myriad host changes, including metabolic changes, which may lead
to the development of liver cirrhosis and hepatocellular carcinoma (HCC) (14, 25–29).
However, the mechanisms by which miR-130a, HCV, HBV, PKLR, and pyruvate metab-
olism are interconnected remain elusive. We hypothesized that miR-130a regulates HCV
and HBV replication through pyruvate metabolism.
The aims of our study were to identify miR-130a target genes and to deﬁne the
molecular mechanism by which miR-130a regulates HCV and HBV replication. Using
bioinformatics tools, we identiﬁed that miR-130a regulates PKLR. Further, we found that
miR-130a regulates both HCV and HBV replication in addition to PKLR. We explored the
regulatory effect of miR-130a on HCV replication in HCV JFH1-infected Huh7.5.1 cells
and primary human hepatocytes (PHHs) and on HBV replication in HepAD38 cells (30)
and HBV infectious supernatant-infected, sodium taurocholate-cotransporting polypep-
tide (NTCP)-transfected Huh7.5.1 cells or PHHs (31). Clustered regularly interspaced
short palindromic repeat (CRISPR)/Cas9 gene editing is a powerful, efﬁcient, and reliable
means of knocking down a target gene (32, 33). We assessed the effects of a series of
target genes on HCV and HBV replication by using CRISPR guide RNA (gRNA), small
interfering RNA (siRNA), miRNA mimic, miRNA inhibitor, and overexpression systems.
We conﬁrmed that the PKLR gene is a direct target of miR-130a. We clariﬁed that
miR-130a regulates HCV and HBV replication as well as PKLR, and therefore (likely)
pyruvate metabolism. Our ﬁndings indicate that the metabolic enzymatic step con-
trolled by PKLR, which results in pyruvate production, plays an important role in HCV
and HBV infections. This previously unrecognized miRNA-regulated antiviral mecha-
nism has implications for the development of host-directed strategies to interrupt the
viral life cycle and prevent establishment of persistent infection for HCV, HBV, and
potentially other viral infections.
RESULTS
Bioinformatic prediction of miR-130a targets.We applied four prediction algorithms,
miRanda, RNAhybrid, TargetScan, and PITA, and obtained 2,152 potential target genes
for miR-130a (https://drive.google.com/open?id0B5t4LtawAMViZ1VxTHlHaWRnblE). We
identiﬁed 534 genes that were predicted by more than two algorithms, among which
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116 genes were related to antiviral responses or liver disease, based on prior publica-
tions on PCR and characterization (https://drive.google.com/open?id0B5t4Ltaw
AMViZ1VxTHlHaWRnblE). These genes were then validated by quantitative PCR (qPCR),
and we found that the expression of three genes, encoding pyruvate kinase in liver and
red cell (PKLR), interleukin-18 binding protein (IL18BP), and the low-density lipoprotein
receptor (LDLR), was signiﬁcantly downregulated by overexpression of miR-130a (by
use of a miR-130a mimic) compared to that with the negative-control mimic treatment
(data not shown).
miR-130a targets PKLR. To determine whether the PKLR, IL18BP, and LDLR genes
are direct targets of miR-130a, we performed dual-luciferase mutation assays using the
miR-130a (AGUGCAA) seed sequence as the binding sequence. We identiﬁed one
potential binding site each in the 3= untranslated regions (UTRs) of PKLR and IL18BP and
three possible binding sites in the 3= UTR of LDLR (Fig. 1). The 3= UTRs of PKLR, IL18BP,
and LDLR were cloned downstream of the ﬁreﬂy luciferase (hLuc) reporter gene in the
reporter vector pEZX-MT06, which was cotransfected with the miR-130a mimic or a
negative-control mimic into Huh7.5.1 cells. We found that overexpression of miR-130a
signiﬁcantly repressed the hLuc/Renilla luciferase (Rluc) ratio (by 45%) when miR-130a
was cotransfected with the wild-type PKLR 3= UTR (PKLR-3=UTR-WT) compared to that
with the negative-control mimic (Fig. 1B). In contrast, no signiﬁcant changes were
observed when miR-130a was cotransfected with an IL18BP-3=UTR-WT or LDLR-
3=UTR-WT plasmid (Fig. 1C to E). These results indicate that PKLR, not IL18BP or LDLR, is
the target gene of miR-130a. To conﬁrm the direct binding between the 3= UTR of PKLR
and the miR-130a seed sequence, we mutated the 3= UTR of PKLR by deleting the
binding site of miR-130a. We found that the hLuc/Rluc ratio in the dual-luciferase
reporter assay was rescued after deleting the binding sites of miR-130a (Fig. 1B). These
results conﬁrm that miR-130a directly targets the 3= UTR of PKLR.
miR-130a regulates HCV replication through targeting of PKLR. miR-130a ex-
pression has been reported to be upregulated in liver tissues of HCV-infected patients
FIG 1 miR-130a directly targeted the PKLR 3= UTR. Huh7.5.1 cells were cotransfected with a cloned
pEZX-MT06 plasmid (containing PKLR-3=UTR-WT, PKLR-3=UTR-Mut, IL18BP-3=UTR-WT, or LDLR-3=UTR-WT)
and a miR-130a mimic or negative-control (Neg) mimic. The hLuc/Rluc ratio serves as a measure of the
inhibition of luciferase expression due to the binding of miR-130a with each cloned 3= UTR. Each
experiment was repeated in triplicate. #, P  0.001 compared to negative-control miRNA. (A) Putative
binding sites of the miR-130a seed sequence on PKLR-3=UTR-WT. PKLR-3=UTR-Mut was constructed by
deleting the matching base sequence. (B) The miR-130a mimic signiﬁcantly reduced PKLR signaling. The
reduction of the hLuc/Rluc ratio disappeared when the binding sites on PKLR were deleted. (C) Putative
binding sites of the miR-130a seed sequence on IL18BP-3=UTR-WT. (D) Sequences of three putative binding
sites of miR-130a on the LDLR 3= UTR. (E) The miR-130a mimic did not affect IL18BP or LDLR signaling.
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(34). We observed an approximately 2-fold increase of miR-130a in JFH1-infected
Huh7.5.1 cells compared to that in uninfected cells (Fig. 2A). We sought to investigate
the association of PKLR with miR-130a and HCV replication. We found that overexpres-
sion of miR-130a led to PKLR reductions at both the mRNA and protein levels in
Huh7.5.1 cells (Fig. 2A to D). The miR-130a mimic did not signiﬁcantly affect the viability
of Huh7.5.1 cells (Fig. 2C). We also observed a signiﬁcant decrease in HCV core protein
in JFH1-infected Huh7.5.1 cells after miR-130a overexpression (Fig. 2D). Finally, we
conﬁrmed the inhibitory effect of miR-130a overexpression on PKLRmRNA (Fig. 2F) and
HCV RNA (Fig. 2G) expression in JFH1-infected PHHs (Fig. 2E to H). The miR-130a mimic
did not signiﬁcantly affect the viability of PHHs (Fig. 2H). We found that miR-130a gRNA
and the miR-130a inhibitor decreased miR-130a expression, by 95%  1% (Fig. 3A and
F) and 65% 3% (data not shown), respectively, and increased PKLR mRNA expression,
by 2.37  0.12- and 1.87  0.1-fold (Fig. 3B and G), respectively, in Huh7.5.1 cells. We
also observed a moderate reduction of PKLR mRNA expression after JFH1 infection (Fig.
3B). As expected, we found that miR-130a knocked down increased HCV replication
2-fold in both the gRNA and miR-130a inhibitor treatment groups compared to that
FIG 2 Overexpression of miR-130a inhibited PKLR expression and HCV replication. The negative-control mimic or miR-130a mimic was transfected
into Huh7.5.1 cells or primary human hepatocytes (PHHs). HCV JFH1 was inoculated into the appropriate wells. miR-130a, HCV RNA, and PKLR
mRNA levels were tested by qPCR. The miR-130a level was normalized to the U6 level, and other selected gene mRNA levels were normalized
to the GAPDH mRNA level, yielding arbitrary units (fold changes). Protein lysates were harvested for Western blotting. *, P  0.05; **, P  0.01;
#, P  0.001 (for comparisons of the indicated miR-130a and negative-control mimic treatments without or with HCV JFH1 infection). (A) The
miR-130a mimic increased the miR-130a level. (B) The miR-130a mimic reduced the PKLR mRNA level. (C) The miR-130a mimic did not affect cell
viability. (D) The miR-130a mimic signiﬁcantly decreased PKLR and HCV core protein levels. (E) The miR-130a mimic signiﬁcantly increased the
miR-130a mRNA level in PHHs. (F) The miR-130a mimic signiﬁcantly reduced the PKLR mRNA level in PHHs. (G) The miR-130a mimic signiﬁcantly
inhibited the HCV RNA level in JFH1-infected PHHs. (H) The miR-130a mimic did not affect cell viability in PHHs.
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in the respective negative-control groups (Fig. 3C and H). miR-130a gRNA signiﬁcantly
increased PKLR and HCV core protein expression in JFH1-infected Huh7.5.1 cells
(Fig. 3D). Similar ﬁndings were observed in OR6 replicon cells, which harbor a genotype
1b full-length HCV replicon with luciferase as a reporter (35, 36). The miR-130a mimic
reduced and the miR-130a inhibitor and gRNA increased HCV replication in OR6 cells
(data not shown). These ﬁndings indicate that miR-130a regulates HCV replication
through the targeting of PKLR in both an HCV JFH1 infection model and an HCV OR6
replicon model.
miR-130a regulates HBV replication through targeting of PKLR. We found that
miR-130a mimic overexpression (Fig. 4A) downregulated the PKLR mRNA level 56% 
6% compared to that with the negative-control mimic treatment in HepAD38 cells (Fig.
4B). The miR-130a mimic modestly reduced the HBV covalently closed circular DNA
(cccDNA) level (Fig. 4C) and signiﬁcantly decreased total HBV DNA, by about 57% 3%
in the HepAD38 cell supernatant (Fig. 4D) and by approximately 40% 2% in HepAD38
cells (Fig. 4E). The miR-130a mimic did not signiﬁcantly affect cell viability (Fig. 4F).
Western blotting conﬁrmed that the miR-130a mimic reduced PKLR and HBcAg protein
levels (Fig. 4G). We found that the HBV DNA level in the supernatant of PHHs exposed
to infectious HBV increased markedly, in a time-dependent manner (Fig. 4H), conﬁrm-
ing that PHHs support HBV infection and replication. However, the miR-130a mimic
signiﬁcantly lowered HBV DNA levels in the supernatants of PHHs compared to those
with untreated cells or cells treated with the negative-control mimic (Fig. 4H). More-
FIG 3 miR-130a gRNA and a miR-130a inhibitor increased PKLR expression and HCV replication. A miR-130a hairpin inhibitor or
CRISPR/Cas9 miR-130a gRNA was used to knock down miR-130a expression. The miR-130a inhibitor, negative-control inhibitor,
miR-130a gRNA, and negative-control gRNA were transfected into Huh7.5.1 cells. HCV JFH1 was inoculated into the appropriate wells
and incubated for 48 h. (A) miR-130a gRNA decreased the miR-130a level. (B) miR-130a gRNA increased the PKLR mRNA level. (C)
miR-130a gRNA promoted HCV RNA replication. (D) miR-130a gRNA increased PKLR and HCV core protein levels. (E) miR-130a gRNA
or the miR-130a inhibitor did not affect cell viability. (F) The miR-130a inhibitor decreased the miR-130a level. (G) The miR-130a
inhibitor increased the PKLR mRNA level. (H) The miR-130a inhibitor promoted HCV RNA replication.
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over, we found that the miR-130a mimic decreased HBV cccDNA and total DNA levels,
by 50% and 80%, respectively, in PHHs 72 h following HBV exposure (Fig. 4I and J).
These ﬁndings collectively indicate that miR-130a regulates HBV replication in He-
pAD38 cells and PHHs.
We further investigated whether miR-130a regulates HBV replication through PKLR.
We found that miR-130a gRNA signiﬁcantly knocked down miR-130a expression (Fig.
5A) and increased the PKLR mRNA level (Fig. 5B) in HepAD38 cells. miR-130a gRNA
signiﬁcantly increased total HBV DNA in HepAD38 cell culture supernatant (Fig. 5C) and
in HepAD38 cells (Fig. 5D), and it modestly increased the HBV cccDNA level (Fig. 5E)
compared to that with negative-control gRNA (Fig. 5A to E). miR-130a gRNA did not
signiﬁcantly affect cell viability (Fig. 5F). Western blotting conﬁrmed that miR-130a
gRNA increased the PKLR and HBcAg protein levels (Fig. 5G). Interestingly, no signiﬁ-
cant change in cccDNA expression in HepAD38 cells was observed with either miR-130a
mimic or miR-130a gRNA treatment (Fig. 4C and 5E). We speculate that the treatment
time (72 h) may have been insufﬁcient to alter cccDNA expression in HepAD38 cells.
PKLR regulates HCV replication. We found that overexpression of PKLR had a
signiﬁcant stimulatory effect on HCV RNA replication (2-fold) and HCV core protein
expression compared to those with the empty vector (Fig. 6A and G). PKLR overex-
pression did not signiﬁcantly affect the viability of Huh7.5.1 and JFH1-infected cells
FIG 4 Overexpression of miR-130a inhibited PKLR expression and HBV replication. A negative-control mimic or miR-130a mimic was transfected
into HepAD38 cells or PHHs. HBV from HepAD38 cells was used to infect cells for 72 h. miR-130a, HBV cccDNA, HBV DNA, and PKLR mRNA in cells,
as well as HBV DNA in supernatants, were quantiﬁed using qPCR. *, P 0.05; **, P 0.01; #, P 0.001 (for comparisons of the indicated miR-130a
and negative-control miRNA treatments). (A) The miR-130a mimic increased the miR-130a level. (B) The miR-130a mimic reduced the PKLR mRNA
level. (C) The miR-130a mimic did not signiﬁcantly affect HBV cccDNA in HepAD38 cells. (D) The miR-130a mimic inhibited the HBV DNA level in
the supernatant. (E) The miR-130a mimic inhibited HBV DNA in HepAD38 cells. (F) The miR-130a mimic did not signiﬁcantly affect the viability
of HepAD38 cells. (G) The miR-130a mimic decreased PKLR and HBcAg protein levels in HepAD38 cells. (H) The miR-130a mimic decreased the
HBV DNA level in the supernatant of PHHs in a time-dependent manner. (I) The miR-130a mimic inhibited HBV cccDNA in PHHs. (J) The miR-130a
mimic inhibited the total HBV DNA level in PHHs.
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(Fig. 6B). In contrast, PKLR gRNA signiﬁcantly knocked down PKLR mRNA (Fig. 6C) and
protein (Fig. 6H) expression and reduced HCV RNA (Fig. 6D) and HCV core protein (Fig.
6H) levels. We also conﬁrmed the inhibitory effect of PKLR knockdown on HCV repli-
cation by using PKLR siRNA (data not shown). However, we found that neither PKLR
gRNA (Fig. 6E) nor PKLR siRNA (data not shown) had an effect on miR-130a expression.
PKLR gRNA did not signiﬁcantly affect the viability of Huh7.5.1 and JFH1-infected cells
(Fig. 6F). Western blotting conﬁrmed that PKLR overexpression increased PKLR and HCV
core expression levels (Fig. 6G) and that PKLR gRNA decreased PKLR and HCV core
protein levels (Fig. 6H). These ﬁndings indicate that PKLR lies downstream of miR-130a.
PKLR regulates HBV replication. We found that PKLR overexpression signiﬁcantly
increased HBV DNA levels in HepAD38 supernatants (Fig. 7A). Furthermore, we used
Huh7.5.1 cells overexpressing NTCP to study HBV, based on previous reports (31, 37).
We found that HBV DNA in the supernatant increased dramatically from day 1 (2.1 
103  0.2  103 copies/ml) to day 3 (12.9  103  0.8  103 copies/ml), indicating the
replication of HBV in NTCP-Huh7.5.1 cells (Fig. 7B). We also found that PKLR gRNA in
NTCP-Huh7.5.1 cells signiﬁcantly lowered HBV DNA in the supernatant compared to the
level for the negative-control-gRNA-transfected NTCP-Huh7.5.1 cells (0.7  104 
0.15  104 copies/ml versus 1.8  104  0.2  104 copies/ml) (Fig. 7C). Furthermore,
we observed a 52%  9% decrease in cccDNA and a 78%  2% reduction in HBV DNA
with PKLR gRNA compared to those with the negative-control gRNA in NTCP-Huh7.5.1
cells (Fig. 7D and E).
Pyruvate plays a key role in regulation of HCV and HBV replication. We next
investigated whether the regulatory effect of miR-130a on HCV and HBV production is
mediated through the enzymatic reaction controlled by PKLR, which results in pyruvate
production. The effects of HCV JFH1 infection were tested in Huh7.5.1 cells in Dulbec-
co’s modiﬁed Eagle’s medium (DMEM), with or without the addition of sodium pyruvate
to the medium. We found that HCV JFH1 infection modestly reduced cell viability
compared to that of uninfected Huh7.5.1 cells. However, there was no signiﬁcant
difference in cell viability between Huh7.5.1 cells and JFH1-infected Huh7.5.1 cells
cultured in DMEM with pyruvate and without pyruvate (Fig. 8A). Moreover, pyruvate
supplementation increased HCV RNA in a dose-dependent manner (Fig. 8B). Higher
FIG 5 miR-130a knockdown increased PKLR expression and HBV replication in HepAD38 cells. miR-130a gRNA or negative-control
gRNA was transfected into HepAD38 cells for 72 h. (A) miR-130a gRNA decreased the miR-130a level. (B) miR-130a gRNA increased
the PKLR mRNA level. (C) miR-130a gRNA increased the HBV DNA level in the HepAD38 cell supernatant. (D) miR-130a gRNA increased
the HBV DNA level in HepAD38 cells. (E) miR-130a gRNA did not signiﬁcantly affect HBV cccDNA levels in HepAD38 cells. (F) miR-130a
gRNA or negative-control gRNA did not signiﬁcantly affect the viability of HepAD38 cells. (G) miR-130a gRNA increased PKLR and
HBcAg protein levels.
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concentrations of pyruvate (2 mM and 5 mM) signiﬁcantly increased HCV RNA levels
compared to those with 0 mM pyruvate in JFH1-infected Huh7.5.1 cells; however, an
even higher concentration of pyruvate (10 mM) did not further enhance HCV RNA levels
(Fig. 8B). We therefore selected 5 mM pyruvate to further investigate the effects of
pyruvate on HCV or HBV replication (Fig. 8 and 9). We conﬁrmed that the miR-130a
mimic (overexpression) decreased PKLR and HCV RNA and protein expression levels
(Fig. 8C to F). Supplemental pyruvate (5 mM) rescued the inhibitory effect of the
miR-130a mimic on HCV RNA replication reduction in JFH1-infected Huh7.5.1 cells (Fig.
8E). Western blotting conﬁrmed that miR-130a decreased the PKLR protein level and
that pyruvate rescued HCV core protein expression (Fig. 8F). The miR-130a mimic
reduced HCV RNA (Fig. 8G) and HBV DNA (Fig. 8H and I) replication levels in PHHs.
Supplemental pyruvate rescued HCV RNA or HBV DNA replication in PHHs (Fig. 8G to
I). We found that PKLR gRNA decreased HCV RNA and HCV core protein expression in
JFH1-infected Huh7.5.1 cells (Fig. 9A to C). Supplemental pyruvate also rescued the
PKLR gRNA inhibition of HCV replication (Fig. 9A and C). We conﬁrmed that PKLR gRNA
knocked down PKLRmRNA and protein expression (Fig. 9B and C). In addition, miR-130a
expression and cell viability were not signiﬁcantly affected by PKLR gRNA or supple-
mental pyruvate (Fig. 9D and E). We further examined PKLR gRNA and pyruvate effects
on HBV replication. We found that PKLR gRNA reduced HBV DNA levels in the super-
natant and in NTCP-Huh7.5.1 cells (Fig. 9F to H). Supplemental pyruvate rescued the
PKLR gRNA inhibition of HBV replication (Fig. 9F to H). These ﬁndings indicate that PKLR
is a critical protein for both HCV and HBV replication.
FIG 6 PKLR regulated HCV replication in JFH1-infected Huh7.5.1 cells. The pPKLR or pEmpty plasmid and the PKLR or negative-control
gRNA were transfected into Huh7.5.1 cells. HCV JFH1 was inoculated into the appropriate wells and incubated for 48 h. (A) PKLR
overexpression increased HCV replication. (B) PKLR overexpression did not affect cell viability. (C) PKLR gRNA decreased the PKLRmRNA
level. (D) PKLR gRNA inhibited HCV RNA replication. (E) PKLR gRNA did not affect miR-130a expression. (F) PKLR gRNA did not affect
cell viability. (G) PKLR overexpression increased HCV core protein levels. (H) PKLR gRNA decreased PKLR and HCV core protein levels.
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DISCUSSION
Pyruvate occupies a critical node in central carbon metabolism, and alterations in
pyruvate metabolism can cause human disease (20). Pyruvate is the end product of
glycolysis; it is generated from PEP and is predominantly converted into fatty acid via
acetyl-coenzyme A (acetyl-CoA) in the liver (38). The conversion of PEP to pyruvate is
catalyzed by pyruvate kinase. There are four tissue-speciﬁc isozymes: L, R, M1, and M2.
The PKL and PKR transcripts are encoded by the same gene (PKLR). PKR is found only
in erythrocytes, whereas PKL is expressed in the liver, kidney, and small intestines (39).
The PKL isozyme is regulated at the transcriptional and posttranscriptional levels in
response to various hormones.
Regulation of pyruvate metabolism also plays a vital role in viral infection, as viruses
rely on host energy and biosynthetic pathways for their replication and proliferation. It
has been shown that HCV and HBV infections are accompanied by host cellular
metabolic reprogramming (40, 41). Previous studies reported reductions in PKLR ex-
pression and pyruvate secretion in chronic HCV infections (40) as well as in HBV replicon
HepG2.2.15 cells (41). There are several reports of decreased PK expression in dengue
virus-infected Huh-7 cells (42) and human cytomegalovirus (HCMV)-infected ﬁbroblasts
(43). However, host cells are able to sense the viral infection and to generate immune
responses to combat and contain the invading virus. This reaction is energy intensive
and is regulated by the host metabolism, including glucose and lipid metabolism.
The regulation of metabolism and antiviral protection strategies by miRNAs has
mostly been investigated independently. miR-130a has been shown to regulate insulin
sensitivity through targeting of GRB10 (44). Insulin is a key hormone that is associated
with glucose metabolism and can regulate PKL expression (45). It has been reported
that interaction between miR-122 and HCV reduces miR-122 bioavailability (14). In this
study, we conﬁrmed the regulatory effect of miR-130a on HCV and HBV. We identiﬁed
PKLR as a direct target gene of miR-130a. miR-130a regulated HCV and HBV replication
through targeting of PKLR. It has previously been demonstrated that overexpression of
miR-130a inhibits HBV DNA replication through targeting of PGC1 and PPAR (13).
FIG 7 PKLR regulated HBV replication. (A) PKLR overexpression increased the HBV DNA level in HepAD38 cell supernatant. (B)
HBV replication in HBV-infected NTCP-Huh7.5.1 cells increased in a time-dependent manner. PKLR gRNA lowered HBV DNA
levels signiﬁcantly compared to those with the negative-control gRNA, in a time-dependent manner. (C) PKLR gRNA reduced
the HBV DNA level in cell culture supernatant. (D) PKLR gRNA reduced the HBV cccDNA level in HBV-infected NTCP-Huh7.5.1
cells. (E) PKLR gRNA reduced the HBV DNA level in HBV-infected NTCP-Huh7.5.1 cells.
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PKLR was also found to be the target gene of miR-338-3p (46). miR-338-3p suppressed
the Warburg effects of hepatocellular carcinoma (HCC) cells by targeting PKLR (46),
indicating that miR-130a likely plays a role in HCC development. We further discovered
the regulatory effect of PKLR and its product pyruvate on HCV and HBV replication.
PKLR overexpression or supplementation with pyruvate increased both HCV and HBV
replication in several infection models. In contrast, knockdown of PKLR expression
reduced HCV and HBV replication, and supplementation with pyruvate rescued the
inhibitory effects of the miR-130a mimic and PKLR gRNA on virus infection.
Other viral infections depend on host cellular metabolism, including glycolysis, to
support viral genome replication and virion assembly (47). For example, pyruvate has
been identiﬁed as a host cellular protein within inﬂuenza virus particles (48). Inﬂuenza
virus replication also induces host pyruvate kinase M production (49). HCV infection
induces glycolysis through an increase in glycolytic enzymes in Huh7 cells (40). HCV
NS5A protein interaction with HK2 induces an enhancement of glucose uptake and
lactic acid production (50). Dengue virus requires glycolysis production for optimal
replication (51). We speculate that decreasing PKLR and pyruvate levels, as well as
FIG 8 Pyruvate supplementation rescued the inhibitory effects of the miR-130a mimic on HCV and HBV replication. Huh7.5.1 cells and
PHHs were cultured as described in Materials and Methods. The miR-130a mimic or negative-control mimic was transfected into Huh7.5.1
cells or PHHs. HCV JFH1 or HBV from HepAD38 cells was inoculated into the appropriate wells for HCV infection or HBV infection as
described in Materials and Methods. Pyruvate was added to the appropriate wells. (A) Pyruvate did not signiﬁcantly affect the viability of
Huh7.5.1 cells and JFH1-infected cells. (B) Pyruvate supplementation increased HCV replication in JFH1-infected cells in a dose-dependent
manner. (C) miR-130a mimic transfection signiﬁcantly increased the miR-130a level in JFH1-infected cells. Supplemental pyruvate did not
affect miR-130a expression. (D) The miR-130a mimic reduced the PKLR mRNA level in JFH1-infected cells. Supplemental pyruvate did not
affect PKLR mRNA expression. (E) Pyruvate supplementation (5 mM) rescued the inhibitory effect of the miR-130a mimic on the HCV RNA
level. (F) Pyruvate supplementation (5 mM) rescued the inhibitory effect of the miR-130a mimic on the HCV core protein level in
JFH1-infected cells. (G) Pyruvate supplementation (5 mM) rescued the inhibitory effect of the miR-130a mimic on HCV replication in PHHs.
(H) Pyruvate supplementation (5 mM) rescued the inhibitory effect of the miR-130a mimic on HBV cccDNA in PHHs. (I) Pyruvate
supplementation (5 mM) rescued the inhibitory effect of the miR-130a mimic on HBV DNA in PHHs.
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subsequent glycolysis levels, inhibit HCV and HBV replication through reduced produc-
tion of ATP and other glycolytic intermediates. Pyruvate was also found to prevent the
death of cells latently infected with Kaposi’s sarcoma-associated herpesvirus (KSHV)
(52).
Our study identiﬁes PKLR and pyruvate as essential metabolic components for HCV
and HBV replication. It further raises the possibility that inhibition of PKLR and pyruvate
may be useful as a short-term measure to restrict HCV or HBV infection. It has been
reported that the interferon (IFN)-induced transmembrane protein IFITM1 is another
potential miR-130a target (34). HCV infection is associated with increased miR-130a
expression in human liver biopsy specimens and in an HCV infection cell culture model,
and IFITM1 overexpression inhibits HCV replication (34). We found that miR-130a gRNA
blocked IFN-stimulated response element (ISRE)-directed signaling (data not shown).
However, PKLR gRNA did not affect ISRE signaling (data not shown). Our ﬁndings
indicate that miR-130a regulation of the IFN-induced ISRE pathway and IFN-stimulated
gene (ISG) innate immunity is independent of PKLR.
Our study systematically investigated the association of the PKLR/pyruvate enzy-
FIG 9 Pyruvate supplementation (5 mM) rescued the inhibitory effects of PKLR gRNA on HCV and HBV replication. HCV
and HBV infections were performed as described in Materials and Methods. Pyruvate was added to the appropriate wells.
*, P  0.05; **, P  0.01; #, P  0.001 (for comparisons of the indicated pyruvate treatments and controls). (A) Pyruvate
supplementation (5 mM) rescued the inhibitory effect of PKLR gRNA on HCV replication in JFH1-infected cells. (B)
Pyruvate supplementation (5 mM) did not affect PKLR mRNA expression in JFH1-infected cells without and with pyruvate.
(C) Pyruvate supplementation (5 mM) rescued the inhibitory effect of PKLR gRNA on the HCV core protein level in
JFH1-infected cells. (D) Pyruvate supplementation (5 mM) did not affect miR-130a expression in JFH1-infected cells. (E)
Pyruvate supplementation (5 mM) did not affect cell viability in JFH1-infected cells. (F) Pyruvate supplementation (5 mM)
rescued the inhibitory effect of PKLR gRNA on the HBV DNA level in HBV-infected NTCP-Huh7.5.1 cell culture supernatant.
(G) Pyruvate supplementation (5 mM) rescued the inhibitory effect of PKLR gRNA on HBV cccDNA replication in
HBV-infected NTCP-Huh7.5.1 cells. (H) Pyruvate supplementation (5 mM) rescued the inhibitory effect of PKLR gRNA on
HBV DNA replication in HBV-infected NTCP-Huh7.5.1 cells.
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matic reaction and HCV/HBV replication, which is regulated by the small noncoding
RNA miR-130a. We therefore propose a miR-130a regulation pathway model in which
miR-130a regulates HCV and HBV replication through PKLR expression and subsequent
pyruvate metabolism. Further understanding of the mechanisms by which miRNA,
PKLR, and pyruvate regulate HCV and HBV replication through ATP and other glycolytic
intermediates may facilitate the development of strategies to prevent establishment of
persistent infection for HCV, HBV, and possibly other viral infections.
MATERIALS AND METHODS
Cell cultures and infectious viruses. Cells of the human hepatoma cell lines Huh7.5.1 and HepAD38
(HBV production is under the control of a tetracycline-regulated promoter) were grown in DMEM with
10% fetal bovine serum (FBS). Huh7.5.1 cells were infected with the genotype 2a strain HCV JFH1
(multiplicity of infection [MOI]  0.2) (JFH1-infected cells) as previously described (53, 54). The human
hepatoma cell line OR6 (35), which harbors full-length genotype 1b HCV RNA and coexpresses Renilla
luciferase, was grown in DMEM supplemented with 10% FBS and 500 g/ml of G418 (Promega, Madison,
WI). Primary human hepatocytes (PHHs) were purchased from Triangle Research Labs (NC, USA) and
cultured according to the manufacturer’s protocol. To reconstitute NTCP expression, Huh7.5.1 cells were
transfected with an NTCP plasmid by use of Lipofectamine LTX (Life Technologies) for 48 h. The
expression levels of NTCP in the candidate cell clones were measured by Western blotting. Infectious HBV
was derived from the culture supernatant of HepAD38 cells, and infections of PHHs and NTCP-Huh7.5.1
cells were carried out as previously described (31, 37, 55, 56). In brief, NTCP-Huh7.5.1 cells or PHHs were
incubated with HBV inoculum for 24 h. The medium was aspirated, the cells were washed three times
with phosphate-buffered saline (PBS), and then the medium was replaced with fresh medium. HBV DNA
in the supernatant or in cells was isolated using a QIAamp DNA minikit (Qiagen, MD, USA). HBV DNA was
quantiﬁed by real-time PCR.
miR-130a mimic, miR-130a inhibitor, siRNAs, CRISPR/Cas9 gRNAs, plasmids, and transfection.
A miR-130a mimic, a miR-130a hairpin inhibitor, and the corresponding negative controls were pur-
chased from GE Dharmacon (Lafayette, CO, USA). GenCRISPR gRNAs for miR-130a and PKLR were
purchased from GenScript USA Inc. (Piscataway, NJ, USA). Protospacer sequences for CRISPR/Cas9
targeting of miR-130a or PKLR were designed by use of CRISPR Design (http://crispr.mit.edu/). The
generated gRNA sequence was cloned into the vector pGS-gRNA-Neo. After transient transfection of
CRISPR/Cas9 gRNA into cells by use of Lipofectamine LTX reagent (Life Technologies), G418 (Life
Technologies) was added for selection of miR-130a or PKLR knockdown cells. PKLR siRNA and negative-
control siRNA were purchased from GE Dharmacon and transfected into cells by use of Lipofectamine
RNAiMax reagent (Thermo Fisher Scientiﬁc). pNTCP, pPKLR, and pEmpty were also transfected into cells
by use of Lipofectamine LTX.
Luciferase assay. The bioinformatics analysis for identiﬁcation of target genes of miR-130a was
performed using the miRanda, RNAhybrid, TargetScan, and PITA software tools (57). Possible target
genes were selected according to a ﬂow diagram (data not shown). To verify whether the three possible
target genes (PKLR, IL18BP, and LDLR) were direct target genes of miR-130a, a dual-luciferase reporter
assay was performed. The PKLR-3=UTR-WT, PKLR-3=UTR-Mut, IL18BP-3=UTR-WT, and LDLR-3=UTR-WT
plasmids were purchased from GeneCopoeia (Rockville, MD). The plasmids were constructed by cloning
the 3= UTRs of PKLR, IL18BP, and LDLR into the dual-luciferase vector pEZX-MT06, downstream of the
ﬁreﬂy luciferase reporter (hLuc) gene. The mutant PKLR reporter plasmid PKLR-3=UTR-Mut was con-
structed by deleting the binding sites of miR-130a in the 3= UTR of PKLR. The vector has a Renilla
luciferase gene (Rluc) as an internal control. For the luciferase reporter assay, Huh7.5.1 cells (1.5  104
cells/per well) were seeded into 96-well plates and incubated overnight. Cells were cotransfected with
50 nM miR-130a mimic (GE Dharmacon, USA) or 50 nM negative control (GE Dharmacon) and 0.1 g/well
plasmid by use of Lipofectamine LTX (Thermo, USA). Fireﬂy and Renilla luciferase activities were
measured by use of a Promega dual-luciferase reporter assay at 24 h posttransfection. The ﬁreﬂy
luciferase/Renilla luciferase activity ratio was calculated to determine the binding between the cloned 3=
UTR and miR-130a. HCV replication in OR6 cells was determined by monitoring Renilla luciferase activity
(Promega, Madison, WI). Cell viability was assessed by use of a Cell Titer-Glo luminescent cell viability
assay kit (Promega, Madison, WI) according to the manufacturer’s protocol.
Pyruvate treatment. For pyruvate treatment studies, the medium from cells grown in 10% FBS-
DMEM containing pyruvate (Corning) was aspirated, washed with PBS three times, and replaced with
10% FBS-DMEM without sodium pyruvate (Corning). Supplemental sodium pyruvate (Thermo Fisher) was
added at speciﬁc concentrations to the appropriate wells.
DNA and RNA isolation and quantiﬁcation. HBV DNA was isolated from cells or supernatants by
use of a QIAamp minikit. Total RNA was isolated by use of a QIA Shredder and RNeasy kit (Qiagen,
Valencia, CA). Reverse transcription was performed by use of a high-capacity cDNA reverse transcription
kit with random primers (Applied Biosystems Inc., Foster City, CA, USA). To quantify gene expression,
quantitative real-time PCR was performed using an ABI QuantStudio 3 system (Applied Biosystems Inc.)
and Power Up SYBR green master mix (Thermo Fisher Scientiﬁc, Waltham, MA). The primers used were
described previously (22, 31). The reactions were performed under the following conditions: 95°C for 3
min followed by 45 cycles of 94°C for 20 s, 60°C for 30 s, and 72°C for 20 s. The mRNA level of each gene
was normalized to that for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to obtain the number
of mRNA arbitrary units (fold change).
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Protein sample preparation and Western blot analysis. Cells were washed with PBS and lysed by
use of RIPA buffer containing a protease inhibitor cocktail (Sigma Life Science and Biochemicals, St. Louis,
MO). For HBV protein preparation, samples were heated at 56°C for 30 min. We loaded equal quantities
of protein (20 g) in all lanes. Protein samples were separated by SDS-PAGE with NuPAGE Novex precast
4 to 12% Bis-Tris gradient gels (Invitrogen, Carlsbad, CA) and blotted onto nitrocellulose membranes. The
membranes were blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline with Tween 20
(TBST). Primary antibodies included mouse anti-human PKLR (Santa Cruz Biotechnology, TX), mouse
anti-HCV core (Fisher Scientiﬁc, Pittsburgh, PA), mouse anti-HBcAg (Abcam, Cambridge, MA), and mouse
anti--actin (Sigma, St. Louis, MO). The secondary antibodies were horseradish peroxidase (HRP)-
conjugated enhanced chemiluminescence (ECL) donkey anti-rabbit IgG and HRP-conjugated ECL sheep
anti-mouse IgG (GE Healthcare Biosciences, Pittsburgh, PA). The blots were subjected to chemilumines-
cence assay by use of an Amersham ECL Western blotting detection kit (GE Healthcare Biosciences,
Pittsburgh, PA).
Data analysis. Data are expressed as means  standard deviations (SD) for at least three indepen-
dent experiments unless otherwise stated. Data analysis was performed using 2-tailed Student’s t test.
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